

## The SMA Daily Life Study - an experience sampling study examining patient-centric outcomes in the daily lives of individuals living with SMA


Yasemin Erbas<sup>1,2,3</sup>, Evgeniya Vedernikova<sup>1,2</sup>, Joran Jongerling<sup>2</sup>, Aki Rintala<sup>4</sup>, Nicole Gusset<sup>1,5</sup>

<sup>1</sup>SMA Europe, Germany, <sup>2</sup>Tilburg University, The Netherlands <sup>3</sup>KU Leuven, Belgium, <sup>4</sup>LAB University of Applied Sciences, Finland, <sup>5</sup>SMA Schweiz, Switzerland

### What is the aim?

#### Explore patient-relevant outcomes

- **Fatigue, pain, and mental health** seem to play an important role in the general **well-being** of patients with SMA, and because they might be valuable as outcome measures for new treatment assessments.
- Research from fields outside of SMA show that these factors have a high level of **between-person**, but also **within-person** variability.
- It remains unclear how these constructs are manifested in the **daily lives of SMA patients**.




### Study details

#### Who will take part?

- ~ 150  from ~  European countries

#### How will we measure?



- Experience Sampling Method (ESM).
  - Participants are prompted multiple times a day for several consecutive days to respond to an electronic questionnaire through a smartphone application.



#### What will we measure?

- Psychological, social and contextual variables.
  - Repeated assessments of such constructs at the momentary level.

### How we will measure patient relevant outcomes?



### What do we expect?

- The results from this study will help us:
  - to better understand how patient-relevant outcomes are manifested in the daily lives of patients,
  - to measure patient-relevant outcomes, taking into account both between-person differences and within-person changes.

### Acknowledgements

We would like to thank CureSMA Industry Collaboration and Tilburg University for their involvement. Also, we deeply appreciate the input from the SMA Europe Adult Committee.

**Spinal Muscular Atrophy (SMA)** is a rare genetic and progressive neuromuscular condition occurring in approximately 1 in 6,000 to 10,000 live births.



yasemin.eras@sma-europe.eu

